지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.1
- 수록면
- 721 - 727 (7page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. Methods: Patients (n=30) were enrolled between September 2015 and April 2016. Twenty-six patients were genotype 1 (1b, n=21; 1a, n=5) and four patients were genotype 2a/2b. Among 21 patients with genotype 1b, Y93H resistance-associated variants (RAVs) were detected in three patients (14.3%). We evaluated sustained virologic response (SVRs) at 12 weeks, as well as relapse and safety. Results: Five patients with genotype 1a and three patients with genotype 1b (RAV positive) received ledipasvir/sofosbuvir for 12 weeks. SVR12 rate was 100% (8/8). Eleven patients with genotype 1b were treatment-naïve and received daclatasvir plus asunaprevir for 24 weeks. SVR12 rate was 91% (10/11). One patient experienced viral breakthrough without RAV at 12 weeks. Seven treatment-experienced patients with genotype 1b received daclatasvir plus asunaprevir for 24 weeks. SVR12 rate was 85.7% (6/7). One patient experienced viral breakthrough with RAV (L31M, Y93H) at 12 weeks. Four patients with genotype 2a/2b received sofosbuvir plus ribavirin for 12 weeks. SVR12 rate was 100% (4/4). No serious adverse event-related discontinuations were noted. Conclusions: New direct acting antiviral treatment achieved high SVRs rates at 12 weeks in CHC patients with hemophilia without serious adverse events.
목차
등록된 정보가 없습니다.
참고문헌 (23)
참고문헌 신청
AASLD/IDSA HCV guidance panel / 2015 / Hepatitis C guidance: AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus / Hepatolog
Afdhal N / 2014 / Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection / N Engl J Med 370 : 1483 ~ 1493
Afdhal N / 2014 / Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection / N Engl J Med 370 : 1889 ~ 1898
European Association for the Study of the Liver / 2017 / EASL recommendations on treatment of hepatitis C 2016 / J Hepatol 66 : 153 ~ 194
Franchini M / 2008 / Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis / J Antimicrob Chemother 61 : 1191 ~ 1200
Afdhal N / 2014 / Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection / N Engl J Med 370 : 1483 ~ 1493
Afdhal N / 2014 / Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection / N Engl J Med 370 : 1889 ~ 1898
European Association for the Study of the Liver / 2017 / EASL recommendations on treatment of hepatitis C 2016 / J Hepatol 66 : 153 ~ 194
Franchini M / 2008 / Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis / J Antimicrob Chemother 61 : 1191 ~ 1200
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
Gut and Liver
2018 .01
-
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
Gut and Liver
2016 .01
-
Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study
Journal of Korean Medical Science
2019 .01
-
Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
Gut and Liver
2017 .01
-
Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection
Gut and Liver
2015 .01
-
Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
Gut and Liver
2016 .01
-
Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
Gut and Liver
2019 .01
-
Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era
Gut and Liver
2017 .07
-
Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study
Gut and Liver
2016 .01
-
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
Clinical and Molecular Hepatology
2017 .01
-
Highly Effective Peginterferon α-2a plus Ribavirin Combination Therapy for Chronic Hepatitis C in Hemophilia in Korea
Clinical and Molecular Hepatology
2015 .01
-
Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
Clinical and Molecular Hepatology
2019 .01
-
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
Clinical and Molecular Hepatology
2018 .01
-
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
Gut and Liver
2020 .01
-
Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
Clinical and Molecular Hepatology
2017 .01
-
Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response
Gut and Liver
2016 .01
-
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
Clinical and Molecular Hepatology
2018 .01
-
고령의 만성 C형 간염 환자에서 Daclatasvir와 Asunaprevir 병용 요법의 유효성 및 안전성 평가
병원약사회지
2018 .01
-
Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China
Gut and Liver
2016 .01
-
Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
Gut and Liver
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0